<DOC>
	<DOCNO>NCT02962895</DOCNO>
	<brief_summary>This study determine dose-response relationship VAY736 key efficacy safety parameter</brief_summary>
	<brief_title>Safety Efficacy VAY736 Patients With Primary Sjogren 's Syndrome ( pSS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<criteria>Fulfilled revise European US consensus criterion pSS Seropositive screening antiRo/SSA antibody Documented salivary/lacrimal gland biopsy result confirm pSS diagnosis prior baseline visit Secondary Sjogren 's syndrome Use investigational drug Active viral , bacterial infection Positive hepatitis B , hepatitis C , HIV tuberculosis test result screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>